A clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. We plan to develop ABP-450 to address the estimated $2.2 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027.
Lead Underwriter
Cantor Fitzgerald & Co., Wells Fargo Securities, LLC
Co-Managers
H.C. Wainwright & Co., LLC, Mizuho Securities USA LLC
